Difference between revisions of "Glioblastoma"

From Libre Pathology
Jump to navigation Jump to search
(pattern: GBM with neuropil islands)
(→‎IHC: moved from neuropathology tumours)
 
(14 intermediate revisions by the same user not shown)
Line 34: Line 34:
*Median survival is measured in months.<ref>{{Cite journal  | last1 = Jubelirer | first1 = SJ. | title = A review of the treatment and survival rates of 138 patients with glioblastoma multiforme. | journal = W V Med J | volume = 92 | issue = 4 | pages = 186-90 | month =  | year =  | doi =  | PMID = 8772403 }}</ref>
*Median survival is measured in months.<ref>{{Cite journal  | last1 = Jubelirer | first1 = SJ. | title = A review of the treatment and survival rates of 138 patients with glioblastoma multiforme. | journal = W V Med J | volume = 92 | issue = 4 | pages = 186-90 | month =  | year =  | doi =  | PMID = 8772403 }}</ref>
*Only about 5% can expect to survive more than three years.<ref name=pmid17785346>{{Cite journal  | last1 = Krex | first1 = D. | last2 = Klink | first2 = B. | last3 = Hartmann | first3 = C. | last4 = von Deimling | first4 = A. | last5 = Pietsch | first5 = T. | last6 = Simon | first6 = M. | last7 = Sabel | first7 = M. | last8 = Steinbach | first8 = JP. | last9 = Heese | first9 = O. | title = Long-term survival with glioblastoma multiforme. | journal = Brain | volume = 130 | issue = Pt 10 | pages = 2596-606 | month = Oct | year = 2007 | doi = 10.1093/brain/awm204 | PMID = 17785346 }}</ref>
*Only about 5% can expect to survive more than three years.<ref name=pmid17785346>{{Cite journal  | last1 = Krex | first1 = D. | last2 = Klink | first2 = B. | last3 = Hartmann | first3 = C. | last4 = von Deimling | first4 = A. | last5 = Pietsch | first5 = T. | last6 = Simon | first6 = M. | last7 = Sabel | first7 = M. | last8 = Steinbach | first8 = JP. | last9 = Heese | first9 = O. | title = Long-term survival with glioblastoma multiforme. | journal = Brain | volume = 130 | issue = Pt 10 | pages = 2596-606 | month = Oct | year = 2007 | doi = 10.1093/brain/awm204 | PMID = 17785346 }}</ref>
*Current classification recognizes three types:
** Glioblastoma, IDH-wildtype (aka primary GBM, ICD-O: 9440/3).
** Glioblastoma, IDH-mutant (aka secondary GBM, ICD-O: 9445/3).
** Glioblastoma, NOS (lack of molecular data).


==Macroscopy==
==Macroscopy==
Line 59: Line 63:
Glioblastoma variants:
Glioblastoma variants:
*Giant cell glioblastoma (ICD-O: 9441/3)
*Giant cell glioblastoma (ICD-O: 9441/3)
** Bizarre multinucleated giant cells.
** Reticulin may be abundant.
** Mean age 44 years, outcome somewhat better than conventional GBM.
** IDH-wildtype, but frequent p53 mutations.
*Epitheloid glioblastoma (ICD-O: 9440/3) <ref>te journal  | last1 = Kleinschmidt-DeMasters | first1 = BK. | last2 = Aisner | first2 = DL. | last3 = Birks | first3 = DK. | last4 = Foreman | first4 = NK. | title = Epithelioid GBMs show a high percentage of BRAF V600E mutation. | journal = Am J Surg Pathol | volume = 37 | issue = 5 | pages = 685-98 | month = May | year = 2013 | doi = 10.1097/PAS.0b013e31827f9c5e | PMID = 23552385 }}</ref>
** Closely packed epithelioid to rhabdoid cells, often dicohesive.
** Xanthomaous changes less common than in PXA.
** Children and young adults, outcome particularly poor.
** Up to 50% BRAF V600E mutations.
*[[Gliosarcoma]] (ICD-O: 9442/3)
*[[Gliosarcoma]] (ICD-O: 9442/3)
*Future variant (in 2016?)
**Epitheloid glioblastoma (50% BRAF V600E mutations) <ref>te journal  | last1 = Kleinschmidt-DeMasters | first1 = BK. | last2 = Aisner | first2 = DL. | last3 = Birks | first3 = DK. | last4 = Foreman | first4 = NK. | title = Epithelioid GBMs show a high percentage of BRAF V600E mutation. | journal = Am J Surg Pathol | volume = 37 | issue = 5 | pages = 685-98 | month = May | year = 2013 | doi = 10.1097/PAS.0b013e31827f9c5e | PMID = 23552385 }}</ref>




Line 71: Line 82:
* Glioblastoma with oligodendroglial component (no improved survival) <ref>{{Cite journal  | last1 = Hegi | first1 = ME. | last2 = Janzer | first2 = RC. | last3 = Lambiv | first3 = WL. | last4 = Gorlia | first4 = T. | last5 = Kouwenhoven | first5 = MC. | last6 = Hartmann | first6 = C. | last7 = von Deimling | first7 = A. | last8 = Martinet | first8 = D. | last9 = Besuchet Schmutz | first9 = N. | title = Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. | journal = Acta Neuropathol | volume = 123 | issue = 6 | pages = 841-52 | month = Jun | year = 2012 | doi = 10.1007/s00401-011-0938-4 | PMID = 22249618 }}</ref>
* Glioblastoma with oligodendroglial component (no improved survival) <ref>{{Cite journal  | last1 = Hegi | first1 = ME. | last2 = Janzer | first2 = RC. | last3 = Lambiv | first3 = WL. | last4 = Gorlia | first4 = T. | last5 = Kouwenhoven | first5 = MC. | last6 = Hartmann | first6 = C. | last7 = von Deimling | first7 = A. | last8 = Martinet | first8 = D. | last9 = Besuchet Schmutz | first9 = N. | title = Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. | journal = Acta Neuropathol | volume = 123 | issue = 6 | pages = 841-52 | month = Jun | year = 2012 | doi = 10.1007/s00401-011-0938-4 | PMID = 22249618 }}</ref>
*Granular cell Glioblastoma <ref>{{Cite journal  | last1 = Schittenhelm | first1 = J. | last2 = Psaras | first2 = T. | title = Glioblastoma with granular cell astrocytoma features: a case report and literature review. | journal = Clin Neuropathol | volume = 29 | issue = 5 | pages = 323-9 | month =  | year =  | doi =  | PMID = 20860896 }}</ref>
*Granular cell Glioblastoma <ref>{{Cite journal  | last1 = Schittenhelm | first1 = J. | last2 = Psaras | first2 = T. | title = Glioblastoma with granular cell astrocytoma features: a case report and literature review. | journal = Clin Neuropathol | volume = 29 | issue = 5 | pages = 323-9 | month =  | year =  | doi =  | PMID = 20860896 }}</ref>
*Glioblastoma with PNET component <ref>{{Cite journal  | last1 = Perry | first1 = A. | last2 = Miller | first2 = CR. | last3 = Gujrati | first3 = M. | last4 = Scheithauer | first4 = BW. | last5 = Zambrano | first5 = SC. | last6 = Jost | first6 = SC. | last7 = Raghavan | first7 = R. | last8 = Qian | first8 = J. | last9 = Cochran | first9 = EJ. | title = Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. | journal = Brain Pathol | volume = 19 | issue = 1 | pages = 81-90 | month = Jan | year = 2009 | doi = 10.1111/j.1750-3639.2008.00167.x | PMID = 18452568 }}</ref>
*Glioblastoma with primitive neuronal component.<ref>{{Cite journal  | last1 = Louis | first1 = DN. | last2 = Perry | first2 = A. | last3 = Reifenberger | first3 = G. | last4 = von Deimling | first4 = A. | last5 = Figarella-Branger | first5 = D. | last6 = Cavenee | first6 = WK. | last7 = Ohgaki | first7 = H. | last8 = Wiestler | first8 = OD. | last9 = Kleihues | first9 = P. | title = The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. | journal = Acta Neuropathol | volume = 131 | issue = 6 | pages = 803-20 | month = Jun | year = 2016 | doi = 10.1007/s00401-016-1545-1 | PMID = 27157931 }}</ref>
**formerly known as: PNET-like component.
**have a tendency to CSF dissemination.<ref>{{Cite journal  | last1 = Perry | first1 = A. | last2 = Miller | first2 = CR. | last3 = Gujrati | first3 = M. | last4 = Scheithauer | first4 = BW. | last5 = Zambrano | first5 = SC. | last6 = Jost | first6 = SC. | last7 = Raghavan | first7 = R. | last8 = Qian | first8 = J. | last9 = Cochran | first9 = EJ. | title = Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. | journal = Brain Pathol | volume = 19 | issue = 1 | pages = 81-90 | month = Jan | year = 2009 | doi = 10.1111/j.1750-3639.2008.00167.x | PMID = 18452568 }}</ref>
*Small cell glioblastoma.
*Small cell glioblastoma.
*Ependymal-like growth patterns.
*Ependymal-like growth patterns.
Line 102: Line 115:
File:Glioblastoma granular cell astrocytoma component.jpg | GBM with granular cell component (WC/jensflorian)
File:Glioblastoma granular cell astrocytoma component.jpg | GBM with granular cell component (WC/jensflorian)
File:Glioblastoma ependymal features.jpg | Glioblastoma with ependymal-like growth pattern (WC/jensflorian)
File:Glioblastoma ependymal features.jpg | Glioblastoma with ependymal-like growth pattern (WC/jensflorian)
https://commons.wikimedia.org/wiki/File:GBM_with_Neuropil_island_HE.jpg | GBM with neuropil-like islands (WC/jensflorian)
File:GBM_with_Neuropil_island_HE.jpg | GBM with neuropil-like islands (WC/jensflorian)
File:AFIP00405522M-GLIOBLASTOMA ARISING IN ASTROCYTOMA.jpg | Spinal cord GBM (AFIP)
File:AFIP00405522M-GLIOBLASTOMA ARISING IN ASTROCYTOMA.jpg | Spinal cord GBM (AFIP)
File:GBM mimicking melanoma.jpg | Glioblastoma mimicking a (amelanotic) melanoma (WC/jensflorian)
File:GBM mimicking melanoma.jpg | Glioblastoma mimicking a (amelanotic) melanoma (WC/jensflorian)
File:GBM layers.jpg | Resection borders in a recurrent GBM (WC/jensflorian)
File:GBM layers.jpg | Resection borders in a recurrent GBM (WC/jensflorian)
File:Glioblastoma-radiation_changes_HE.jpg | Radiation changes in a recurrent GBM (WC/jensflorian)
File:Glioblastoma-radiation_changes_HE.jpg | Radiation changes in a recurrent GBM (WC/jensflorian)
File:GBM_nested_epithelial.jpg | Nested epitheloid appearance in a GBM specimen (WC/jensflorian)
Image:Glioblastoma_%281%29.jpg | Glioblastoma - pseudopalisading of tumour cells (WC)
Image:Glioblastoma_-_high_mag.jpg | Glioblastoma with fragment of near-normal white matter - high mag. (WC)
Image:Anaplastic_astrocytoma_-_very_high_mag_-_cropped.jpg | Anaplastic astrocytoma - very high mag. (WC)
</gallery>
</gallery>


www:
www:
Line 117: Line 136:
*[[MAP2]] +ve.
*[[MAP2]] +ve.
*[[IDH-1]] -ve (95%).
*[[IDH-1]] -ve (95%).
**+ve if developed from lower grade astrocytoma (secondary GBM).
**+ve if developed from lower grade astrocytoma (secondary GBM) -> classify tumor as Glioblastoma, IDH-mutant.
*[[WT-1]] +ve (cytoplasm).
*[[WT-1]] +ve (cytoplasm).
*p53 +ve (70%).
*p53 +ve (70%).
Line 124: Line 143:
*panCK -ve (except for GBM with epithelial component).
*panCK -ve (except for GBM with epithelial component).
*[[ATRX]]: +ve (no loss, nuclei)
*[[ATRX]]: +ve (no loss, nuclei)
**-ve if developed from lower grade astrocytoma (secondary GBM).
**-ve if developed from lower grade astrocytoma (secondary GBM).  
*EMA: Dot-like expression less common than in [[ependymoma]]s.
*EMA: Dot-like expression less common than in [[ependymoma]]s.
*MIB-1 usu. 15-30%, but varies greatly.
*MIB-1 usu. 15-30%, but varies greatly.
Line 132: Line 151:
File:Wilms tumor protein wt1 immunohistocehmistry glioblastoma.JPG | WT1 immunostaining in GBM (WC/jensflorian)
File:Wilms tumor protein wt1 immunohistocehmistry glioblastoma.JPG | WT1 immunostaining in GBM (WC/jensflorian)
File:Glioblastoma P53.jpg | GBM with strong p53 immunreactivity (WC/jensflorian)
File:Glioblastoma P53.jpg | GBM with strong p53 immunreactivity (WC/jensflorian)
File:IDH1 GBM 20x.jpg | IDH1 R132H immunreactivity in a secondary GBM (WC/Marvin101)
File:Glioblastoma Ck7.jpg|CK7 staining in glioblastoma with epithelial component (WC/jensflorian)
File:Glioblastoma Ck7.jpg|CK7 staining in glioblastoma with epithelial component (WC/jensflorian)
File:GBM_with_Neuropil_island_MIB1.jpg|Reduced proliferation in neuropil-like islands (MIB1).
File:GBM_with_Neuropil_island_MIB1.jpg|Reduced proliferation in neuropil-like islands (MIB1).
File:GBM_with_Neuropil_island_Syn.jpg Synaptophysin immunoreactivity in neuropil-like islands (WC/jensflorian).
File:GBM_with_Neuropil_island_Syn.jpg |Synaptophysin immunoreactivity in neuropil-like islands (WC/jensflorian).
Image:Anaplastic_astrocytoma_-_gfap_-_very_high_mag.jpg | Anaplastic astrocytic tumor cells - GFAP - very high mag. (WC)
</gallery>
</gallery>


==Molecular==
==Molecular==
*IDH1/2 sequencing in cases below 55 years is mandatory to separate between Glioblastoma, IDH-wildtype and Glioblastoma IDH-mutant.
** In cases above 55 years, negative IDH1 R132H immunohistochemistry may be sufficient.
* 70% of IDH-wildtype glioblastoma show chr.7 gain and chr.10 loss.<ref>{{Cite journal  | last1 = Ceccarelli | first1 = M. | last2 = Barthel | first2 = FP. | last3 = Malta | first3 = TM. | last4 = Sabedot | first4 = TS. | last5 = Salama | first5 = SR. | last6 = Murray | first6 = BA. | last7 = Morozova | first7 = O. | last8 = Newton | first8 = Y. | last9 = Radenbaugh | first9 = A. | title = Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. | journal = Cell | volume = 164 | issue = 3 | pages = 550-63 | month = Jan | year = 2016 | doi = 10.1016/j.cell.2015.12.028 | PMID = 26824661 }}</ref>
*Seen in inherited tumor syndromes:
*Seen in inherited tumor syndromes:
**Lynch-Syndrome
**[[Lynch syndrome]]
**[[Neurofibromatosis 1]]
**[[Neurofibromatosis 1]]
**Li-Fraumeni-Syndrome
**[[Li-Fraumeni syndrome]]
**Turcot-Syndrome
**Turcot-Syndrome


Line 153: Line 177:
**PI3K-pathway genes (7-10%).
**PI3K-pathway genes (7-10%).


*Pediatric glioblastoma
**are morphologically indistinct from adult GBM.
**show frequent H3F3A mutations  and PDGFRA mutations (Note: H3F3A K27M mutations are classified as [[Astrocytoma#H3.3_K27M_mutated_glioma_of_the_midline|K27 mutated midline glioma]]).
**Consider Epithelioid GBM, when BRAF V600E mutated.


*Diagnostic/therapeutic relevant markers:
*Diagnostic/therapeutic relevant markers:
**MGMT promoter methylation status  
**[[MGMT]] promoter methylation status<ref>{{Cite journal  | last1 = Quillien | first1 = V. | last2 = Lavenu | first2 = A. | last3 = Karayan-Tapon | first3 = L. | last4 = Carpentier | first4 = C. | last5 = Labussière | first5 = M. | last6 = Lesimple | first6 = T. | last7 = Chinot | first7 = O. | last8 = Wager | first8 = M. | last9 = Honnorat | first9 = J. | title = Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. | journal = Cancer | volume = 118 | issue = 17 | pages = 4201-11 | month = Sep | year = 2012 | doi = 10.1002/cncr.27392 | PMID = 22294349 }}</ref>
**Absence of LOH 1p/19q (otherwise classify tumor as [[oligodendroglioma]]).
**Absence of LOH 1p/19q (otherwise classify tumor as [[oligodendroglioma]]).<ref>{{Cite journal  | last1 = Masui | first1 = K. | last2 = Mischel | first2 = PS. | last3 = Reifenberger | first3 = G. | title = Molecular classification of gliomas. | journal = Handb Clin Neurol | volume = 134 | issue =  | pages = 97-120 | month =  | year = 2016 | doi = 10.1016/B978-0-12-802997-8.00006-2 | PMID = 26948350 }}</ref>


==See also==
==See also==

Latest revision as of 09:07, 14 April 2022

Glioblastoma
Diagnosis in short

Glioblastoma. H&E stain.
LM astrocytic differentiation, nuclear atypia, necrosis, microvascular proliferation, +/-pseudopalisading necrosis
Subtypes gliosarcoma
LM DDx anaplastic astrocytoma
IHC GFAP +ve, IDH-1 -ve/+ve
Site brain, spinal cord
Radiology intra-axial
Prognosis very poor
Clin. DDx metastatic brain tumours

Glioblastoma a very common malignant primary brain tumour in adults. It has a very poor prognosis.

It was previously known as glioblastoma multiforme, abbreviated GBM.

General

  • Median survival is measured in months.[1]
  • Only about 5% can expect to survive more than three years.[2]
  • Current classification recognizes three types:
    • Glioblastoma, IDH-wildtype (aka primary GBM, ICD-O: 9440/3).
    • Glioblastoma, IDH-mutant (aka secondary GBM, ICD-O: 9445/3).
    • Glioblastoma, NOS (lack of molecular data).

Macroscopy

Features:

  • Usu. in white matter.
    • central necrotic core.
    • ill-defined borders.
    • yellowish to dark-brown changes.
    • midline shift due to tumor mass.
  • In the corpus callosum as bihemispheric "butterfly glioma"

  • Ring-enhancement in GBM (WC/Hellerhoff)

  • Left insular GBM macroscopy (WC/Sbrandner)

  • "Butterfly glioma" (WC/AFIP)

Microscopic

Features:

  • Astrocytic tumour with:
    • Nuclear atypia.
    • Necrosis.
    • Endothelial proliferation (AKA microvascular proliferation).
    • +/-"Pseudopalisading necrosis" - tumour cells lined-up like a picket fence around necrotic areas.

Glioblastoma variants:

  • Giant cell glioblastoma (ICD-O: 9441/3)
    • Bizarre multinucleated giant cells.
    • Reticulin may be abundant.
    • Mean age 44 years, outcome somewhat better than conventional GBM.
    • IDH-wildtype, but frequent p53 mutations.
  • Epitheloid glioblastoma (ICD-O: 9440/3) [3]
    • Closely packed epithelioid to rhabdoid cells, often dicohesive.
    • Xanthomaous changes less common than in PXA.
    • Children and young adults, outcome particularly poor.
    • Up to 50% BRAF V600E mutations.
  • Gliosarcoma (ICD-O: 9442/3)


Morphological patterns in Glioblastoma:

  • Lipidized (foamy)cells [4]
  • Adipocyte-like maturation [5]
  • Rhabdoid glioblastoma (focal loss of INI-1) [6]
  • Melanotic glioblastoma [7]
  • Glioblastoma with oligodendroglial component (no improved survival) [8]
  • Granular cell Glioblastoma [9]
  • Glioblastoma with primitive neuronal component.[10]
    • formerly known as: PNET-like component.
    • have a tendency to CSF dissemination.[11]
  • Small cell glioblastoma.
  • Ependymal-like growth patterns.
  • Glioneuronal tumor with neuropil-like islands.[12]

Images

  • Core features of GBM: Necrosis, MVP and mitoses (WC/jensflorian)

  • Anaplastic cells in GBM (WC/jensflorian)

  • Endothelial proliferations in GBM (WC/jensflorian)

  • Mitotic activity in GBM (WC/jensflorian)

  • Pseudopalisading necrosis in GBM (WC/jensflorian)

  • Diffuse brain infiltration in GBM (WC/jensflorian)

  • MVP adjacent to tumor infiltration border in GBM (WC/jensflorian)

  • GBM - low mag. (WC)

  • GBM juxtaposed with near normal white matter - intermed. mag. (WC)

  • GBM juxtaposed with near normal white matter - high mag. (WC)

  • GBM - very high mag. (WC)

  • GBM - high mag. (WC)

  • Extreme nuclear enlargement in a GBM - very high mag. (WC)

  • Giant cell glioblastoma (WC/jensflorian)

  • Adenoid growth pattern in GBM (WC/jensflorian)

  • Adenoid growth pattern in GBM (AFIP)

  • Epitheloid glioblastoma (WC/jensflorian)

  • GBM with PNET component (WC/jensflorian)

  • GBM with PNET component (WC/jensflorian)

  • GBM with oligodendroglial component (WC/jensflorian)

  • Nuclear pleomorphism in with oligodendroglial component (WC/jensflorian)

  • GBM with granular cell component (WC/jensflorian)

  • Glioblastoma with ependymal-like growth pattern (WC/jensflorian)

  • GBM with neuropil-like islands (WC/jensflorian)

  • Spinal cord GBM (AFIP)

  • Glioblastoma mimicking a (amelanotic) melanoma (WC/jensflorian)

  • Resection borders in a recurrent GBM (WC/jensflorian)

  • Radiation changes in a recurrent GBM (WC/jensflorian)

  • Nested epitheloid appearance in a GBM specimen (WC/jensflorian)

  • Glioblastoma - pseudopalisading of tumour cells (WC)

  • Glioblastoma with fragment of near-normal white matter - high mag. (WC)

  • Anaplastic astrocytoma - very high mag. (WC)


www:

IHC

  • GFAP +ve (cytoplasm).
  • MAP2 +ve.
  • IDH-1 -ve (95%).
    • +ve if developed from lower grade astrocytoma (secondary GBM) -> classify tumor as Glioblastoma, IDH-mutant.
  • WT-1 +ve (cytoplasm).
  • p53 +ve (70%).
  • Neurofilament -ve.
  • Synaptophysin -ve (residual Cortex may be +ve).
  • panCK -ve (except for GBM with epithelial component).
  • ATRX: +ve (no loss, nuclei)
    • -ve if developed from lower grade astrocytoma (secondary GBM).
  • EMA: Dot-like expression less common than in ependymomas.
  • MIB-1 usu. 15-30%, but varies greatly.

  • GFAP immunostaining in GBM (WC/Marvin 101)

  • WT1 immunostaining in GBM (WC/jensflorian)

  • GBM with strong p53 immunreactivity (WC/jensflorian)

  • CK7 staining in glioblastoma with epithelial component (WC/jensflorian)

  • Reduced proliferation in neuropil-like islands (MIB1).

  • Synaptophysin immunoreactivity in neuropil-like islands (WC/jensflorian).

  • Anaplastic astrocytic tumor cells - GFAP - very high mag. (WC)

Molecular

  • IDH1/2 sequencing in cases below 55 years is mandatory to separate between Glioblastoma, IDH-wildtype and Glioblastoma IDH-mutant.
    • In cases above 55 years, negative IDH1 R132H immunohistochemistry may be sufficient.
  • 70% of IDH-wildtype glioblastoma show chr.7 gain and chr.10 loss.[13]
  • Most common alterations (TCGA[14])
    • Tp53 (42% of the tumors mutated)
    • PTEN (33%).
    • NF1 (21%).
    • EGFR (18%).
    • RB1 (11%).
    • PI3K-pathway genes (7-10%).
  • Pediatric glioblastoma
    • are morphologically indistinct from adult GBM.
    • show frequent H3F3A mutations and PDGFRA mutations (Note: H3F3A K27M mutations are classified as K27 mutated midline glioma).
    • Consider Epithelioid GBM, when BRAF V600E mutated.
  • Diagnostic/therapeutic relevant markers:

See also

References

  1. ↑ Jubelirer, SJ.. "A review of the treatment and survival rates of 138 patients with glioblastoma multiforme.". W V Med J 92 (4): 186-90. PMID 8772403.
  2. ↑ Krex, D.; Klink, B.; Hartmann, C.; von Deimling, A.; Pietsch, T.; Simon, M.; Sabel, M.; Steinbach, JP. et al. (Oct 2007). "Long-term survival with glioblastoma multiforme.". Brain 130 (Pt 10): 2596-606. doi:10.1093/brain/awm204. PMID 17785346.
  3. ↑ te journal | last1 = Kleinschmidt-DeMasters | first1 = BK. | last2 = Aisner | first2 = DL. | last3 = Birks | first3 = DK. | last4 = Foreman | first4 = NK. | title = Epithelioid GBMs show a high percentage of BRAF V600E mutation. | journal = Am J Surg Pathol | volume = 37 | issue = 5 | pages = 685-98 | month = May | year = 2013 | doi = 10.1097/PAS.0b013e31827f9c5e | PMID = 23552385 }}
  4. ↑ Kepes, JJ.; Rubinstein, LJ. (May 1981). "Malignant gliomas with heavily lipidized (foamy) tumor cells: a report of three cases with immunoperoxidase study.". Cancer 47 (10): 2451-9. PMID 7023643.
  5. ↑ Rickert, CH.; Riemenschneider, MJ.; Schachenmayr, W.; Richter, HP.; Bockhorn, J.; Reifenberger, G.; Paulus, W. (Jul 2009). "Glioblastoma with adipocyte-like tumor cell differentiation--histological and molecular features of a rare differentiation pattern.". Brain Pathol 19 (3): 431-8. doi:10.1111/j.1750-3639.2008.00199.x. PMID 18691268.
  6. ↑ Hiroyuki, M.; Ogino, J.; Takahashi, A.; Hasegawa, T.; Wakabayashi, T. (Feb 2015). "Rhabdoid glioblastoma: an aggressive variaty of astrocytic tumor.". Nagoya J Med Sci 77 (1-2): 321-8. PMID 25797998.
  7. ↑ Jaiswal, S.; Agrawal, V.; Vij, M.; Sahu, RN.; Jaiswal, AK.; Behari, S.. "Glioblastoma with melanotic differentiation.". Clin Neuropathol 29 (5): 330-3. PMID 20860897.
  8. ↑ Hegi, ME.; Janzer, RC.; Lambiv, WL.; Gorlia, T.; Kouwenhoven, MC.; Hartmann, C.; von Deimling, A.; Martinet, D. et al. (Jun 2012). "Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.". Acta Neuropathol 123 (6): 841-52. doi:10.1007/s00401-011-0938-4. PMID 22249618.
  9. ↑ Schittenhelm, J.; Psaras, T.. "Glioblastoma with granular cell astrocytoma features: a case report and literature review.". Clin Neuropathol 29 (5): 323-9. PMID 20860896.
  10. ↑ Louis, DN.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, WK.; Ohgaki, H.; Wiestler, OD. et al. (Jun 2016). "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.". Acta Neuropathol 131 (6): 803-20. doi:10.1007/s00401-016-1545-1. PMID 27157931.
  11. ↑ Perry, A.; Miller, CR.; Gujrati, M.; Scheithauer, BW.; Zambrano, SC.; Jost, SC.; Raghavan, R.; Qian, J. et al. (Jan 2009). "Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.". Brain Pathol 19 (1): 81-90. doi:10.1111/j.1750-3639.2008.00167.x. PMID 18452568.
  12. ↑ Ishizawa, K.; Hirose, T.; Sugiyama, K.; Kageji, T.; Nobusawa, S.; Homma, T.; Komori, T.; Sasaki, A.. "Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.". Clin Neuropathol 31 (2): 67-76. PMID 22385787.
  13. ↑ Ceccarelli, M.; Barthel, FP.; Malta, TM.; Sabedot, TS.; Salama, SR.; Murray, BA.; Morozova, O.; Newton, Y. et al. (Jan 2016). "Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.". Cell 164 (3): 550-63. doi:10.1016/j.cell.2015.12.028. PMID 26824661.
  14. ↑ Verhaak, RG.; Hoadley, KA.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, MD.; Miller, CR.; Ding, L. et al. (Jan 2010). "Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.". Cancer Cell 17 (1): 98-110. doi:10.1016/j.ccr.2009.12.020. PMID 20129251.
  15. ↑ Quillien, V.; Lavenu, A.; Karayan-Tapon, L.; Carpentier, C.; Labussière, M.; Lesimple, T.; Chinot, O.; Wager, M. et al. (Sep 2012). "Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients.". Cancer 118 (17): 4201-11. doi:10.1002/cncr.27392. PMID 22294349.
  16. ↑ Masui, K.; Mischel, PS.; Reifenberger, G. (2016). "Molecular classification of gliomas.". Handb Clin Neurol 134: 97-120. doi:10.1016/B978-0-12-802997-8.00006-2. PMID 26948350.
Retrieved from "https://librepathology.org/w/index.php?title=Glioblastoma&oldid=52006"